On November 8, 2022, the Quanzhou Industry-University-Research Fund Matchmaking Conference, hosted by the Quanzhou Municipal People's Government and jointly organized by Quanzhou Science and Technology Bureau and Quanzhou Financial Holding Group Co.
, was successfully held
At this conference, Han's Pharmaceutical Project under Hanshi United Group signed an on-site contract, which marked the official landing of Han's Pharmaceutical Project in Quanzhou, Fujian Province, planning to build an international-oriented stem cell new drug industrialization base and a cell therapy and regenerative medicine clinical transformation center
With the theme of "Starting from Science and Technology, Becoming Finance", the conference aims to deepen the docking cooperation between industry, education and research funds, promote the deep integration of the "four chains" of innovation chain, industrial chain, capital chain and talent chain, and accelerate the transformation of
scientific and technological achievements.
Zhang Jinzhu, Deputy Secretary-General of Quanzhou Municipal Government, Wang Xiaoyang, Director of the Municipal Science and Technology Bureau, Wang Wenkun, General Manager of Quanzhou Financial Holding Group, leaders of various county (city, district) governments, relevant departments of the city, five major state-owned groups under the city, and county-level science and technology departments, as well as representatives of scientific research institutes, financial institutions, investment institutions, universities and industry enterprises in Quanzhou attended the grand event
Discuss topics such as "realizing the close integration of scientific and technological innovation and financial innovation", and explore new paths
for innovation and development.
Han Zhongchao, academician of the French National Academy of Technical Sciences, foreign communication academician of the French National Academy of Medical Sciences, Han United Group and chairman of Han's Pharmaceutical, was invited to deliver an online speech
At present, the global cell drug market has broad prospects, stem cells and immune cell products, the rapid development of the cell industry, the market scale is gradually expanding, in recent years, cell research and application has become an important indicator
to measure the development of a country's life science and medicine.
China's cell industry due to the late start, the entire industrial chain is still not perfect compared with foreign countries, although there is no stem cell drug on the market, but the field is currently in a stage of rapid development, the market potential is huge
Since 2015, China has attached great importance to the development of cell therapy technology from the policy point of view, and has successively introduced a series of important policies and regulations, creating a good policy environment for the new pattern of industry development, and also bringing new opportunities for the transformation of cell innovative technologies and products, which shows the affirmation and importance
of cell science and technology at the national level to improve the development of medicine and national health.
For the country, cells are a strategic biological resource, which is related to the development of national security and the well-being of hundreds of millions of people; For the life science and health industry, cell resources are the fundamental guarantee and foundation of the development of industry and technology
The 20th National Congress of the Communist Party of China formulated ambitious national development goals, and proposed to strengthen the national strategic scientific and technological strength and improve the overall efficiency of
the national innovation system.
The Quanzhou Municipal Party Committee and Municipal Government carried out the two-wheel drive deployment of "strengthening industry and rejuvenating the city", and deeply implemented the special action
of "grasping innovation and promoting application".
These policies and deployments provide valuable opportunities
for innovative companies.
Quanzhou in Fujian Province is located in the southeast coastal area, with convenient transportation, high-end biological talents, high acceptance of emerging industries, and profound scientific and technological innovation genes, which has unique advantages
for the development of stem cell drug industry.
The signing of cooperation between Han's Pharmaceutical and Fengze District, Quanzhou City, Fujian Province can give full play to their respective advantages and mutual benefit, or will promote the development of "new stem cell drugs" into a new era and accelerate the industrialization of
new stem cell drugs.
Academician Han Zhongchao, co-chairman of Han's, said that the landing of Han's pharmaceutical project in Quanzhou, Fujian Province is an important part of the strategic layout of Han's joint cell industrialization strategy, with the help of local industrial agglomeration advantages, talent advantages, policy support advantages, etc.
, it is conducive to accelerating the development of Han's pharmaceutical sector, promoting the transformation of stem cell scientific and technological achievements, and helping domestic cell products to be launched as soon as possible, so that this new type of biotechnology can quickly go to the people, and at the same time help to establish a new standard of stem cell science and technology, and create another international business card in Quanzhou
In recent years, Hanshi Pharmaceutical has cooperated with Fujian Medical University to carry out scientific research, cooperated with Fuzhou Union Medical College Hospital to carry out clinical research on new drugs, and the results won the first prize of Provincial Medical Science and Technology, assisted Quanzhou Second Affiliated Hospital to establish a respiratory stem cell laboratory, carried out stem cell clinical transformation and application research, and will further deepen cooperation in the future to carry out multidisciplinary research in different directions and continuously improve scientific and technological competitiveness
Han's Pharmaceutical is a biopharmaceutical company with stem cell regenerative medicine as the core, with a series of self-developed core intellectual property rights of stem cell new drugs, won many scientific and technological awards, and set up a rich stem cell drug R&D pipeline, involving more than a dozen indications, of which 6 stem cell class 1 new drugs have obtained implied approval for clinical trials, and 1 stem cell new drug IND application has been accepted
With more than 20 years of scientific and technological achievements and independent intellectual property rights, the company is committed to quickly and steadily realizing the industrialization of new stem cell drug technology and manufacturing stem cell drugs
used by the people.